Delivery Order SPE2DB20D1109-SPE2DB25FP56P
- Not listed
- The Defense Logistics Agency awarded a $10,805.10 delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be performed at the vendor's Corporate...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $7,203.44 for Xolair 150 mg/mL syringes, with an ultimate completion date of June 24, 2025. This competitive award, issued on June 2, 2025, carries a firm fixed price structure with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken, PA 19428....
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $14,406.80 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes. The contract, issued on June 24, 2025, with an ultimate completion date of July 16, 2025, was awarded on a non-competitive, firm fixed-price basis. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order valued at $25,932.24 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes. This competitively awarded, firm fixed-price contract is scheduled for completion by August 21, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,440.70 for XOLAIR 150 mg/mL syringes, with an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract representing a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $8,644.08 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes, with an ultimate completion date of August 27, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $4,322.04 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes on July 18, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, competitively awarded delivery order represents a non-set-aside procurement issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract is for performance at AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded a Delivery Order valued at $1,440.70 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes, with an ultimate completion date of September 9, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under a larger indefinite delivery contract vehicle. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $10,393.14 firm fixed price delivery order to AmerisourceBergen Drug Corp for XOLAIR 300 mg/2 mL syringes on July 9, 2025, with completion targeted for July 30, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $4,322.04 delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes, with an ultimate completion date of May 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, serves as a prime contractor through its...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP56PDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,322.04 to AmerisourceBergen Drug Corp for Xolair 150 mg/mL syringes, with an ultimate completion date of September 3, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's existing pharmaceutical supply contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which functions as a comprehensive global pharmaceutical support vehicle. The IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. The delivery of Xolair—a specialty biologic medication—exemplifies the company's role in fulfilling specialized pharmaceutical needs across federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 8/12/25 |